CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adu...
Phase 3
Barcelona, Spain and 3 other locations
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatiti...
Phase 3
Esplugues de Llobregat, Barcelona [Barcelona], Spain and 78 other locations
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...
Phase 3
Esplugues de Llobregat, Spain and 88 other locations
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...
Phase 3
Esplugues de Llobregat, Barcelona [Barcelona], Spain and 95 other locations
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...
Phase 3
Barcelona, Spain and 96 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Barcelona, Spain and 540 other locations
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Phase 3
Barcelona, Catalonia, Spain and 556 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Barcelona, Spain and 194 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...
Phase 3
Barcelona, Spain and 193 other locations
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Phase 3
Barcelona, Spain and 342 other locations
Clinical trials
Research sites
Resources
Legal